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ABSTRACT  
 
Objective: To compare the degree of impaired placentation in pregnancies which 
develop preeclampsia (PE) in women with and without chronic hypertension (CH). 
 
Methods: The data for this study were derived from prospective screening for adverse 
pregnancy outcomes in women with singleton pregnancies attending for their first routine 
hospital visit at 11+0-13+6 weeks’ gestation. This visit included recording of maternal 
characteristics and medical history and measurements of mean arterial pressure (MAP), 
uterine artery pulsatility index (UTPI), serum placental growth factor (PLGF) and serum 
pregnancy associated plasma protein-A (PAPP-A). The measured biomarkers were 
converted to multiples of the median (MoM) after adjustment for pregnancy 
characteristics and MoM values in women with CH that developed PE (n=283) were 
compared to those of women without CH that developed PE (n=2,236). 
 
Results: In both groups with and without CH the measurements of MAP and UTPI were 
increased, whereas those of PLGF and PAPP-A were decreased and the deviation from 
normal in all biomarkers decreased with advancing gestational age at delivery with PE. 
There was no significant difference between those with and without CH in the slope of 
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the regression line of Log10 MoM biomarker values with gestational age at delivery with 
PE for any of the biomarkers. However, there was a significant difference in the 
intercepts and coefficients of biomarkers in the two groups; in the CH group, compared 
to those without CH, the MAP MoM was higher (p<0.0001), UTPI MoM was lower 
(p=0.004), placental growth factor MoM was higher (p=0.001) and PAPP-A MoM was 
higher (p=0.015).  
 
Conclusion: In pregnancies that develop PE the degree of impaired placentation, 
reflected in high UTPI and low PLGF and PAPP-A at 11-13 weeks’ gestation, is less in 
women with than without CH. 
 
 
 
Key Words: Chronic hypertension; preeclampsia; uterine artery pulsatility index; serum 
placental growth factor; serum pregnancy associated plasma protein-A; mean arterial 
pressure. 
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Introduction 
 
Preeclampsia (PE) complicates 2-3% of pregnancies and the risk for PE , increases with 
advancing maternal age, increasing weight, Afro-Caribbean and South Asian racial 
origin, previous pregnancy with PE, conception by in vitro fertilization and  medical 
history of chronic hypertension (CH), diabetes mellitus and systemic lupus 
erythematosus or antiphospholipid syndrome1 The greatest risk factor for PE is medical 
history of CH, which is found in 1-2% of pregnancies; the risk of both preterm and term 
PE, after adjustment for maternal demographic characteristics, medical history and 
obstetric history, is 5-6 times higher in women with CH than in those without CH.2 
 
In PE, particularly preterm PE, there is impairment in the physiologic process of 
trophoblastic invasion of the maternal spiral arteries and their remodeling from tortuous 
narrow muscular vessels into large non-muscular channels.3-5 Reduced perfusion of the 
placenta causes oxidative stress that triggers off release of trophoblast-derived factors, 
which enter the maternal circulation and cause generalized endothelial dysfunction and 
an exaggerated inflammatory response that underlines many of the changes observed in 
PE.6-11 In some women with medical disorders, such as CH, there is endothelial 
dysfunction even before pregnancy and it was proposed that in such cases PE can 
develop in the absence of impaired placentation; the pre-existing endothelial dysfunction 
is exacerbated by the physiological burden of pregnancy, as normal pregnancies carry a 
low-grade systemic inflammatory response.12-15  
 
The aim of this study in pregnancies that developed PE was to examine possible 
differences between women with and without CH in measures of impaired placental 
perfusion, assessed by uterine artery Doppler, and placental function, reflected in 
decreased maternal serum levels of placental growth factor (PLGF) and pregnancy 
associated plasma protein-A (PAPP-A) at 11-13 weeks’ gestation. 
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse outcomes in 
women with singleton pregnancies attending for their first routine hospital visit at King’s 
College Hospital, London, UK (between March 2006 and July 2015) and Medway 
Maritime Hospital, Kent, UK (between February 2007 and November 2015). This visit, 
which was held at 11+0-13+6 weeks of gestation, included recording of maternal 
characteristics and medical history1 and measurements of uterine artery pulsatility index 
(UTPI) by transabdominal color Doppler ultrasound,16 mean arterial pressure (MAP) by 
validated automated devices and standardized protocol,17 and serum concentration of 
PLGF and PAPP-A (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, 
Waltham, USA). Gestational age was determined from the measurement of the fetal 
crown-rump length.18 Written informed consent was obtained from women who agreed to 
participate in the study, which was approved by the Ethics Committee of each 
participating Hospital. Data on pregnancy outcomes were collected from the hospital 
maternity records and the women’s general medical practitioners. 
 
The inclusion criteria for this study were pregnancies that developed PE and delivered 
phenotypically normal babies that were live born or stillborn at >24 weeks’ gestation. The 
diagnosis of PE was made according to the guidelines of the International Society for the 
Study of Hypertension in Pregnancy.19 The systolic blood pressure should be >140 mm 
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Hg and/or the diastolic blood pressure should be >90 mmHg on at least two occasions 
four hours apart developing after 20 weeks’ gestation in a previously normotensive 
woman and in addition there should be significant proteinuria (>300 mg in 24 hours, or 
two readings of at least ++ on dipstick analysis of midstream or catheter urine specimen, 
if no 24-hour collection is available). In CH diagnosis of superimposed PE requires the 
development of significant proteinuria after 20 weeks’ gestation in a previously non 
proteinuric woman. 
 
Statistical analysis  
 
Comparison of the maternal characteristics and obstetric history between pregnancies 
with and without CH was by the χ2-square test or Fisher’s exact test for categorical 
variables and Mann-Whitney U-test for continuous variables, respectively.  
 
The measured MAP, UTPI, PLGF and PAPP-A were converted to multiples of the 
median (MoM) after adjustment for maternal characteristics and medical history. 20-23 
Regression analysis was used to determine the association between the MoM values of 
each biomarker and gestational age at delivery with PE and the slope and intercepts of 
the regression lines were compared for pregnancies with and without CH. Comparison of 
slopes between regression lines in the two groups was carried out with Pothoff analysis 
by introducing interaction terms in the linear regression analysis.24 If there was no 
significant difference between slopes in the two groups, then a comparison of intercepts 
of the regression lines was assessed by examining the coefficient (95% confidence 
intervals) for CH.25 
 
The statistical software package SPSS Statistics 20.0 (SPSS Inc., Chicago, Ill., USA) 
and MedCalc Statistical Software version 17.2 (MedCalc Software bvba, Ostend, 
Belgium) were used for data analyses. 
 
 
Results 
 
During the study period, first-trimester screening was carried out in 283 pregnancies with 
CH that developed PE and 2,236 pregnancies without CH that developed PE. Delivery at 
<37 weeks’ gestation occurred in 35.7% (102 of 286) of the CH group and in 27.0% (615 
of 2,274) in those without CH. The maternal characteristics and medical and obstetric 
history of the two groups are compared in Table 1. In pregnancies with CH, compared to 
those without CH, the median maternal age and weight were higher, and there was a 
higher incidence of women of Afro-Caribbean racial origin, those with medical history of 
SLE/APS and type II diabetes mellitus and parous women with a previous pregnancy 
with PE. 
 
There was no significant difference between those with and without CH in the slope of 
the regression line of Log10 MoM biomarker values with gestational age at delivery with 
PE for MAP (p=0.282), UTPI (p=0.138), PLGF (p=0.115) or PAPP-A (p=0.435) (Table 2). 
However, there was a significant difference in the intercepts and coefficients of 
biomarkers in the two groups; in the CH group, compared to those without CH, the MAP 
MoM was higher (p<0.0001), UTPI MoM was lower (p=0.004), placental growth factor 
MoM was higher (p=0.001) and PAPP-A MoM was higher (p=0.015) (Figure 1).  
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Discussion 
 
Principal findings of this study 
 
The findings of this study demonstrate that in pregnancies that develop PE both in 
women with CH and in those without CH, at 11-13 weeks’ gestation first, MAP and UTPI 
are increased and PLGF and PAPP-A are decreased, and second, the deviation from 
normal in these biomarkers decreases with advancing gestational age at delivery with 
PE and they are therefore greater for early than late PE. The slope of the relationship 
between biomarker levels with gestational age at delivery is similar in those with CH and 
those without CH, but for the same severity of PE, reflected in the gestational age at 
delivery, in the CH group the deviation in UTPI, PLGF and PAPP-A is lower. In 
pregnancies with CH the MAP at 11-13 weeks’ gestation is inevitably considerably higher 
in those with than without CH. 
 
The findings of the study provide support for the hypothesis that in medical conditions 
with coexisting endothelial dysfunction, such as CH, the degree of placental impairment 
necessary to trigger off the development of PE may be less than in pregnancies without 
such preexisting endothelial dysfunction.12,13 
 
Strengths and limitations 
 
The strengths of this study for PE are first, examination of a large population of 
pregnancies with and without CH that developed PE, second, use of a specific 
methodology and appropriately trained doctors to measure UTPI and MAP, third, use of 
automated machines to provide accurate measurement of maternal serum concentration 
of metabolites that have been shown to be altered in pregnancies associated with 
impaired placentation, fourth, expression of the values of the biomarkers as MoMs after 
adjustment for factors that affect the measurements, and fifth, comparison of levels of 
biomarkers in women with and without CH by taking into account the gestational age at 
delivery with PE. 
 
A limitation of the study is that we did not include measurement of potential biomarkers 
of inflammation and endothelial dysfunction. In previous studies we reported that at 11-
13 weeks’ gestation in pregnancies that develop PE there are increased maternal 
circulating levels of the inflammatory factors pentraxin 3, matrix metalloproteinase-9 and 
the soluble receptor-1 of the tumor necrosis factor-α, as well as P-selectin, a marker of 
platelet activation.26-29 We found that the altered levels in these biomarkers were not 
associated with the degree of impairment in placental perfusion reflected in UTPI. 
However, we did not investigate whether there are differences in the levels of these 
biomarkers between pregnancies with CH and those without CH. 
 
Comparison with previous studies 
 
Several studies have documented that development of PE is associated with first-
trimester increase in UTPI and MAP and decrease in serum PLGF and PAPP-A.16,30-35 In 
this study we compared biomarker levels in women with and without CH. Previous 
studies have documented the association between CH and endothelial dysfunction and 
inflamation.36,37 However, we could not identify reports comparing first-trimester 
biomarkers in PE in women with and without CH. 
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Clinical implications of the study 
 
The incidence of CH is 1-2% and in these women the risk of PE is >20%; in this respect 
a history of CH is the strongest risk factor for PE, compared to other factors in maternal 
demographic characteristics and medical history.1,2 Effective first-trimester screening for 
PE is provided by a combination of maternal factors and MAP, UTPI, PLGF and PAPP-
A.34,35 In pregnancies with CH that develop PE, the smaller deviation from normal in 
UTPI, PLGF and PAPP-A is compensated by the considerably higher MAP. The rationale 
for first-trimester prediction of PE from a combination of maternal factors and 
biomarkers33,34 is that pharmacological intervention with low-dose aspirin in the high-risk 
group could potentially reduce the incidence of the disease.38,39 It is uncertain whether 
the potential benefit from low-dose aspirin is mediated through an effect on improving 
placentation or through its anti-inflammatory properties and the extent to which this 
medication will be equally effective in prevention of PE in pregnancies with and without 
CH remains to be determined. 
This article is protected by copyright. All rights reserved.
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Table 1. Maternal characteristics and medical history in pregnancies with PE in women 
with and without CH.  
Maternal characteristics Chronic hypertension (n=283) 
No chronic hypertension 
(n=2,236) 
GA at recruitment (weeks), median (IQR) 12.6 (12.3-13.1) 12.6 (12.3-13.1) 
Age (years), median (IQR) 34.7 (31.0-38.7) ** 30.6 (25.9-34.8) 
Weight (kg), median (IQR) 85.0 (71.0-98.0) ** 72.0 (62.8-85.0) 
Height (cm), median (IQR) 163 (160-168) 163 (159-168) 
Racial origin   
     Caucasian, n (%) 113 (39.9) 1,394 (62.3) 
     Afro-Caribbean, n (%) 154 (54.4) ** 655 (29.3) 
     South Asian, n (%) 11 (3.9) 103 (4.6) 
     East Asian, n (%) 3 (1.1) 36 (1.6) 
     Mixed, n (%) 2 (0.7) 48 (2.1) 
Method of conception   
     Spontaneous, n (%) 268 (94.7) 2,125 (95.0) 
     Ovulation drugs, n (%) 5 (1.8) 27 (1.2) 
     In vitro fertilization, n (%) 10 (3.5) 84 (3.8) 
Cigarette smoking, n (%) 18 (6.4) 166 (7.4) 
History of SLE / APS, n (%) 7 (2.5) ** 6 (0.3) 
History of diabetes mellitus   
     Type I, n (%) 4 (1.4) 19 (0.8) 
     Type II, n (%) 13 (4.6) ** 19 (0.8) 
Family history of PE 28 (9.9) 176 (7.9) 
Family history of diabetes mellitus   
     First degree, n (%) 54 (19.1) 369 (16.5) 
     Second degree, n (%) 25 (8.8) 161 (7.2) 
Obstetric history   
     Nulliparous, n (%) 95 (33.6) 1,440 (64.4) 
     Parous with previous PE, n (%) 87 (30.7) ** 254 (11.4) 
     Parous without previous PE, n (%) 101 (35.7) ** 542 (24.2) 
 
GA = gestational age; IQR = interquartile range; SLE = systemic lupus erythematosus; APS = 
antiphospholipid syndrome; PE = preeclampsia. **p<0.0001 
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Table 2. Pothoff analysis for comparison of slopes of regression lines in pregnancies 
with and without chronic hypertension for relationship of each biomarker with gestational 
age at delivery. 
 
Variables in equation Coefficient (95% CI) Error P value 
MAP    
Intercept 0.077 (0.055 to 0.099) 0.011 <0.0001 
Gestational age -0.001 (-0.002 to -0.001) 0.0001 <0.0001 
Chronic hypertension 0.073 (0.015 to 0.131) 0.030 0.014 
Chronic hypertension x GA -0.001 (-0.002 to 0.001) 0.001 0.282 
UTPI    
Intercept 0.539 (0.465 to 0.611) 0.037 <0.0001 
Gestational age -0.013 (-0.015 to -0.011) 0.001 <0.0001 
Chronic hypertension 0.115 (-0.073 to 0.302) 0.095 0.230 
Chronic hypertension x GA -0.004 (-0.009 to 0.001) 0.003 0.138 
PLGF    
Intercept -0.889 (-1.030 to -0.748) 0.072 <0.0001 
Gestational age 0.020 (0.016 to 0.023) 0.002 <0.0001 
Chronic hypertension -0.254 (-0.647 to 0.139) 0.200 0.205 
Chronic hypertension x GA 0.009 (-0.002 to 0.019) 0.005 0.115 
PAPP-A    
Intercept -0.587 (-0.724 to -0.450) 0.070 <0.0001 
Gestational age 0.013 (0.010 to 0.017) 0.002 <0.0001 
Chronic hypertension 0.189 (-0.179 to 0.557) 0.187 0.314 
Chronic hypertension x GA -0.004 (-0.014 to 0.006) 0.005 0.435 
 
GA = Gestational age; MAP = Mean arterial pressure; UTPI = Uterine artery pulsatility index; 
PLGF = Placental growth factor; PAPP-A = Pregnancy associated plasma protein-A. 
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Figure legend 
 
Figure 1. Scatter diagram and regression line for the relationship between mean arterial 
pressure, uterine artery pulsatility index, serum placental growth factor and pregnancy 
associated plasma protein-A multiple of the median (MoM) and gestational age at 
delivery in pregnancies with preeclampsia with chronic hypertension (red circles and red 
lines) and without chronic hypertension (grey circles and grey lines). 
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Gestational age at delivery with PE (wks) 
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